New blood thinner may improve dialysis outcomes in sepsis patients
NCT ID NCT07518303
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two blood thinners used during continuous dialysis in adults with sepsis and acute kidney injury. About 1,162 participants will receive either nafamostat mesylate or standard citrate anticoagulation. The main goal is to see which approach reduces death, ongoing dialysis need, or persistent kidney problems within 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nafamostat mesylate
What this could lead to
If nafamostat works better than citrate, it could reduce death, kidney failure, or the need for ongoing dialysis in sepsis patients.
What could go wrong
This is a phase 4 trial, but results may not apply to all patients. Nafamostat could cause bleeding or other side effects, and the benefit over citrate is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••